CD262 antibodies, mouse

CD262 antibodies, mouse

Clone: MD5-1-3C2 | Dilution: 1:10
CD262 is a 55 kDa protein expressed on leukocytes, placenta cells, liver cells and some tumor cells and tumor cell lines (such as NIH-3T3). CD262 is also known as DR5, TRAIL-R2, and TNFRSF10B. CD262 is a receptor for TRAIL, its binding induces apoptosis by activating the NF-κB pathway.

Alternative Names

TNFRSF10B, DR5, KILLER, Ly98, MK, TRAIL-R2, TRICK2A, TRICK2B, TRICKB

Technical specifications

  • Antigen: CD262
  • Clone: MD5-1-3C2
  • Isotype: hamster IgG
  • Alternative names of antigen: TNFRSF10B, DR5, KILLER, Ly98, MK, TRAIL-R2, TRICK2A, TRICK2B, TRICKB
  • Entrez Gene ID: 21933
  • Molecular mass of antigen [kDa]: 37
  • Distribution of antigen: heart, leukocytes, liver, lung, ovary, pancreas, placenta, spleen, thymocytes
  • Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
  • Fixation: The antibody is suited for staining of formaldehyde-fixed cells.
  • Storage: Store protected from light at 2–8 °C. Do not freeze.
  • Available conjugates: FITC, PE, APC, PE-Vio770, APC-Vio770, PerCP-Vio700, Biotin
  • Selected References

    1. Grisendi, G. et al. (2010) Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 70(9): 3718-3729
    2. Hayakawa, Y. et al. (2004)
      NK cell TRAIL eliminates immature dendritic cells
      in vivo
      and limits dendritic cell vaccination efficacy.
      J. Immunol. 172(1): 123-129
    3. Iannello, A. et al. (2009) Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells. J. Virol. 83(12): 5999-6010
    4. Sato, K. et al. (2005) TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J. Immunol. 174(7): 4025-4033
    5. Shanker, A. et al. (2008) Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J. Natl. Cancer Inst. 100(9): 649-662
    6. Takeda, K. et al. (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 4(199): 437-448
Product options: 10

Product information

Size
Order no.
Price

CD262-FITC, mouse

  • MD5-1-3C2
  • 1:10
  • For research use only
30 µg in 1 mL (1)
130-102-478
-

CD262-PE, mouse

  • MD5-1-3C2
  • 1:10
  • For research use only
30 µg in 1 mL (1)
130-102-565
-

CD262-APC, mouse

  • MD5-1-3C2
  • 1:10
  • For research use only
30 µg in 1 mL (1)
130-102-513
-

CD262-PE-Vio770, mouse

  • MD5-1-3C2
  • 1:10
  • For research use only
9 µg in 300 µL (1)
130-105-695
-

CD262-PE-Vio770, mouse

  • MD5-1-3C2
  • 1:10
  • For research use only
30 µg in 1 mL (1)
130-105-648
-

CD262-APC-Vio770, mouse

  • MD5-1-3C2
  • 1:10
  • For research use only
9 µg in 300 µL (1)
130-105-696
-

CD262-APC-Vio770, mouse

  • MD5-1-3C2
  • 1:10
  • For research use only
30 µg in 1 mL (1)
130-105-649
-

CD262-PerCP-Vio700, mouse

  • MD5-1-3C2
  • 1:10
  • For research use only
9 µg in 300 µL (1)
130-105-697
-

CD262-PerCP-Vio700, mouse

  • MD5-1-3C2
  • 1:10
  • For research use only
30 µg in 1 mL (1)
130-105-650
-

CD262-Biotin, mouse

  • MD5-1-3C2
  • 1:10
  • For research use only
30 µg in 1 mL (1)
130-101-919
-